This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

A Phoenix doctor weighs in on the potential impact of FDA plans to limit COVID booster access to high-risk groups, raising cost and care concerns.

Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The vaccine is expected to remain available for anyone who is at least 65 or who has a medical condition, leaving many ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

A group of experts who advise the US Food and Drug Administration on its vaccine decisions voted unanimously Thursday to make ...

The vaccine advisory committee for the Food and Drug Administration met Thursday to discuss potential changes to the formula for COVID-19 vaccines for 2025-2026.

The FDA has told vaccine manufacturers to expand the warning labels on their COVID-19 shots with more information about the ...